Some others don’t see the global in gray shadows. Illustration title, you can think binary about Covid-19. If you get the disease, there are only two results: a quick return to fitness for those with symptoms or death.
If it were that simple.
There is growing evidence of the long-term serious effects of Covid-19 in an increasing number of patients. In addition, even mild or asymptomatic carriers of the new coronavirus would possibly have Effects of Covid-19 on other organs, adding the heart.
A transparent breakdown of coronavirus cases in the 3 categories of asymptomatic, benign and severe is too simplistic; In addition, the false perception that if a user is asymptomatic or sick, morbidity (never) or symptoms do not disappear completely is implicit in this categorization. Respectively.
Daily figures attended by policymakers and public health officials with cases, hospitalizations, deaths and the number of Covid-19 patients recovered (if reported; some jurisdictions do not report cures).
Recoveries can be strictly explained as those that are no longer positive for coronavirus tests, but this does not allow us the fact that many supposedly recovered patients are still sick, and their recoveries are equally incomplete.
In fact, doctors say that one of the many mysteries surrounding the new coronavirus is how fast recovery can be for some and incredibly slow for others. The so-called “long haul”: a subset of Covid-19 patients, many of whom have never been hospitalized: it has a wide variety of persistent symptoms months after contracting coronavirus.
Earlier this week, The Washington Post published an article about Covid-19 survivors in Bergamo, Italy, 50% of whom say they have fully recovered. Doctors interviewed in Bergamo discussed a follow-up exam they took this summer with long-term patients. Of the 750 patients examined, approximately 30% still have lung scarring and breathing problems, and 30% have inflammation and clotting problems, adding to heart abnormalities and arterial obstructions.
A Dutch examination published in June indicated that a subset of patients in the “slightly symptomatic” category were found to have been particularly beaten through Covid-19 over long periods, several months.
In the Netherlands, the Lung Foundation, in collaboration with Maastricht University and the CIRO group, interviewed 1,622 Covid-19 patients who had reported a variety of long-term effects of their disease; 91% of patients had not been hospitalized. The average age of the patients interviewed is 53 years.
Nearly 88% of patients reported persistent intense fatigue, while nearly 75% had difficulty breathing non-stop. Other persistent symptoms included chest tension (45% of patients), headaches and muscle aches (40% and 36%, respectively), upper pulse (30%) dizziness (29%) Perhaps the maximum unexpected location was that 85% of the patients surveyed were healthy before receiving Covid-19. A month or more after contracting the disease, only 6% were healthy.
And, in a study completed this summer, among 86 patients admitted by Covid-19 to 3 hospitals in Austria from April to early June, respectively, 39% and 15% of patients were still suffering from shortness of breath and heavy coughing. after its initial diagnosis.
Ed Yong of The Atlantic has produced several brilliant articles about the lifestyles of the long-distance phenomenon and the plight of patients facing a future.
The lifestyles of Covid-1nine and the SARS-CoV-2 virus that causes the disease have been known for almost nine months, and needless to say that the exact pathogenesis has been fully characterized.
In particular, what remains doubtful are the reasons why the differential has an effect on the disease in which they test positive for coronavirus.
Long-along routes do not complicate the Covid-19 symbol, but asymptomatic routes, some of which have organs that have inflammation and damage, make it even more disorderly.
Preliminary, and not yet published, knowledge revealed that in the United States, about 15% of a pattern of college athletes who had contracted coronavirus, most of whom had mild symptoms or no symptoms, had been diagnosed with myocarditis. caused by a viral infection, such as coronavirus, which can lead to immediate or central rhythms and even sudden cardiac death.
Despite more than 195,000 Covid-19 deaths in the United States over the course of 6 months, in some circles, underestimating coronavirus has been an obstinately persistent and popular topic of the pandemic.
Audio tapes released from talks between Bob Woodward and President Trump indicate, for example, that the president admitted to downplaying the impact of the new coronavirus in March, at a time when perhaps a more vigilant and proactive stance could have stopped the initial attack on the virus.
In the following months, members of Trump’s leadership described the coronavirus as “disappearing,” “disappearing,” “weakening,” and inconsecent for the vast majority who contract it. In July, President Trump said that “99% of others are doing perfectly well with the coronavirus. These cases are absolutely harmless. “
Of course, more than 1% of cases are symptomatic, whether severe or mild, and tens of thousands of patients have persistent symptoms that classify them as long-lasting, and even asymptomatic organization wants to be monitored.
Full policy and updates on the coronavirus
The Dutch organization CIRO, a treatment, resources and wisdom center, specializes in the care of patients with chronic diseases, adding acute and chronic lung diseases.
I am an independent fitness analyst with over 22 years of experience in fitness care and pharmaceutical analysis. Specifically, I analyze the price (costs and benefits) of
I am an independent fitness analyst with over 22 years of experience in fitness care and pharmaceutical analysis. Specifically, I analyze the price (costs and benefits) of biological and pharmaceutical products, patient access to prescription drugs, regulatory frameworks for drug progression, and reimbursement. , and ethics in the distribution of fitness resources. I have more than 110 publications in industry journals and peer-reviewed journals, as well as newspapers and periodicals. I have also presented my paintings at industry, commercial and educational conferences. From 1999 to 2017, he was an associate professor of studies at the Tufts Center for the Study of Drug Development. Prior to my appointment to Tufts, I was a postdoctoral fellow at the University of Pennsylvania and finished my PhD in Economics at the University of Amsterdam. PhD, I was a control representative at Accenture in The Hague, Netherlands. Currently, I work as a freelancer in a variety of studies, including teaching and writing projects.